Statements (90)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2018
gptkb:FDA |
| gptkbp:atccode |
N04 BA02
|
| gptkbp:availability |
prescription only
|
| gptkbp:bioavailability |
variable
|
| gptkbp:brand |
gptkb:Inbrija
|
| gptkbp:class |
dopaminergic agents
|
| gptkbp:clinical_trial |
Cohort Study
Phase 3 well tolerated improved motor function reduced off time |
| gptkbp:clinical_use |
off episodes in Parkinson's disease
|
| gptkbp:competitors |
other Parkinson's drugs
|
| gptkbp:contains |
levodopa
|
| gptkbp:contraindication |
narrow-angle glaucoma
history of melanoma hypersensitivity to levodopa |
| gptkbp:dosage_form |
gptkb:Spider-Man
gptkb:capsule 5 inhalations per day |
| gptkbp:drug_interactions |
iron supplements
MAO inhibitors antipsychotics dopamine agonists iron salts |
| gptkbp:effective_date |
FDA approved
2018-12-21 |
| gptkbp:excretion |
urine
|
| gptkbp:financial_support |
available through manufacturer
not for use as a primary treatment |
| gptkbp:formulation |
inhalation powder
|
| gptkbp:healthcare |
gptkb:neuroscientist
|
| https://www.w3.org/2000/01/rdf-schema#label |
Inbrija
|
| gptkbp:indication |
motor symptoms of Parkinson's disease
off episodes of Parkinson's disease |
| gptkbp:ingredients |
levodopa
|
| gptkbp:invention |
patented
|
| gptkbp:label |
FDA guidelines
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:market |
ongoing
adverse events reported |
| gptkbp:marketed_as |
gptkb:2018
gptkb:Inbrija |
| gptkbp:marketing_authorization_holder |
gptkb:Acorda_Therapeutics
|
| gptkbp:mechanism_of_action |
converts to dopamine in the brain
|
| gptkbp:metabolism |
peripheral and central
|
| gptkbp:minimum_dosage |
1 inhalation per episode
|
| gptkbp:packaging |
single-dose inhaler
|
| gptkbp:patient_education |
monitor for side effects
necessary for proper use instruct on proper inhaler use |
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
increases dopamine levels
rapid onset of action rapid absorption dopamine agonist |
| gptkbp:price |
varies by insurance
varies by pharmacy |
| gptkbp:provides_guidance_on |
Parkinson's disease management
|
| gptkbp:related_products |
Duopa
Rytary Sinemet |
| gptkbp:research |
Efficacy Study
|
| gptkbp:research_focus |
Parkinson's disease treatment
|
| gptkbp:route_of_administration |
inhalation
|
| gptkbp:route_of_elimination |
renal
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:safety_measures |
not recommended in breastfeeding
not recommended in pregnancy may cause hallucinations monitor for dyskinesia risk of impulse control disorders |
| gptkbp:service_frequency |
as needed
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
dizziness
headache nausea cough throat irritation serious adverse events |
| gptkbp:storage |
room temperature
|
| gptkbp:structure |
C9 H11 NO4
|
| gptkbp:treatment |
improved motor function
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
gptkb:neurodegenerative_diseases
treatment of Parkinson's disease |
| gptkbp:bfsParent |
gptkb:Acorda_Therapeutics
|
| gptkbp:bfsLayer |
5
|